Poziotinib did not show an improved response rate among previously treated non-small cell lung cancer patients with a specific genetic mutation, but additional cohorts in the Phase II study are ongoing.
CEO Joe Turgeon said in an interview that the company aims to focus more on developing drugs for larger, broader and more lucrative oncology markets.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
The company plans a Phase II study next year in a subset of non-small cell lung cancer patients who usually don't respond to existing therapies.